Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128

Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36

Published:2022-12 Issue: Volume:46 Page:135-136
ISSN:2666-1683
Container-title:European Urology Open Science
language:en
Short-container-title:European Urology Open Science

Author:

Gómez Rivas Juan,Gandaglia Giorgio,Montorsi Francesco

Publisher

Elsevier BV

Subject

Urology

Reference10 articles.

1. Studies on prostatic cancer: I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate;Huggins;CA Cancer J Clin,1972

2. EAU guidelines on prostate cancer;Mottet,2022

3. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer;Hamdy;N Engl J Med,2016

4. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) trial 30891;Studer;J Clin Oncol,2006

5. Active surveillance plus enzalutamide monotherapy vs active surveillance alone in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT randomized clinical trial;Shore;JAMA Oncol,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials;Prostate Cancer and Prostatic Diseases;2024-04-08